Publications by authors named "J B Mannick"
Using a modified Delphi process, we engaged 28 experts in clinical trials, geriatrics, and research translation to determine if there were consensus around what clinical endpoints should be used for trials evaluating the efficacy of interventions to prevent or treat multiple age-related conditions. Four focus groups developed themes. Statements related to those themes were circulated back to participants in a survey.
View Article and Find Full Text PDFArticle Synopsis
- Recent advancements in aging research and drug discovery connect basic research with clinical applications, aiming to promote healthy longevity in humans.* -
- The Aging Research and Drug Discovery Meeting in 2023 highlighted key areas such as AI, biomarkers, geroscience, and clinical trials focused on enhancing healthspan.* -
- The meeting emphasized the importance of combining generative AI with innovative biological technologies to tackle age-related diseases and extend healthy lifespans.*
Article Synopsis
- The growth of aging biology research is focusing on finding and assessing longevity interventions for humans, making biomarkers of aging essential tools for these efforts.
- A lack of standards and consensus on what makes a reliable aging biomarker currently limits their development and application in clinical settings.
- The article proposes a framework for categorizing aging biomarkers, discussing validation processes, and identifying challenges that need future research to facilitate their use in clinical trials and practices.
Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses ("Gerodiagnostics").
View Article and Find Full Text PDF